scholarly journals Synthetic progestogen-oestrogen therapy and uterine changes

1967 ◽  
Vol 20 (5) ◽  
pp. 731-738 ◽  
Author(s):  
J. G. Azzopardi ◽  
I. Zayid
1976 ◽  
Vol 35 (02) ◽  
pp. 403-414 ◽  
Author(s):  
Terence Davies ◽  
Gillian Fieldhouse ◽  
George P. McNicol

SummaryThe effects on the haemostatic mechanism of oestrogen therapy, given to prevent bone loss in post-menopausal women, have been investigated. Oestriol succinate was given orally to 10 women at a level of 2 mg/day for 1 month and for a further 3 months with incremental increase of 2 mg each month. 6 of the 10 women were subsequently treated with 25 μg/day orally of ethinyl oestradiol. Oestriol succinate therapy resulted in a small increase in the level of factor VII, a decrease in factor VIII concentration and increased sensitivity of platelets to aggregating agents. Ethinyl oestradiol treatment resulted in much more widespread changes with marked increases in coagulation factors VII, VIII, IX and X, decreased levels of antithrombin and dramatic increases in circulating plasminogen levels and euglobulin lysis activity. The data suggested that the nature of oestrogens employed therapeutically is important in determining the qualitative and quantitative effect of oestrogen therapy on components of the haemostatic mechanism.


1973 ◽  
Vol 74 (3) ◽  
pp. 449-460 ◽  
Author(s):  
Patrick C. Walsh ◽  
Ronald S. Swerdloff ◽  
William D. Odell

ABSTRACT Serum follicle stimulating hormone (FSH) and luteinizing hormone (LH) were measured by radioimmunoassay in a group of elderly men following castration and oestrogen therapy. Prior to orchiectomy, mean serum concentrations of LH and FSH were within the normal range. Two days following castration, serum LH concentrations increased in all eight patients; higher levels of LH were subsequently measured in all but one patient after periods of time ranging from 49 to 210 days. Serum FSH levels, measured in three patients following castration, increased in a pattern parallel to LH changes. Ethinyl oestradiol (EOe) in doses ranging from 5 to 300 μg/day was administered to ten men who had been castrated 3 to 72 months earlier. Oestrogen treatment suppressed both LH and FSH in a parellel manner in nine of ten patients. LH was first suppressed to intact levels in one of eight patients treated with 20 μg/day of EOe, in two of six patients treated with 50 μg/day, and in one patient by 80 μg/day. FSH was not suppressed to precastration levels until 50 μg/day of EOe was administered; this dose suppressed three of six patients. Higher doses of EOe (150–300 μg/day) suppressed both LH and FSH to levels below the sensitivity of the assay. These data fail to demonstrate any differential effect of oestrogen on LH and FSH release.


1994 ◽  
Vol 59 (3) ◽  
pp. 429-434 ◽  
Author(s):  
N. F. G. Beck ◽  
M. C. G. Davies

AbstractAn investigation was conducted to determine the effect of mating at puberty or third oestrus or after pre-mating oestrogen and progestagen therapy, designed to mimic the changes that occur in plasma oestrogen and progesterone concentrations during the 1st, 2nd or 3rd oestrous cycles, on fertility in ewe lambs. Twenty-five ewe lambs were mated at puberty on mean date of 18 October and 21 were mated at third oestrus on 3 December. Of these, 28% and 81% of animals mated at puberty and third oestrus lambed, respectively (P < 0·05). A similar number of ewe lambs were mated within 24 h of ram introduction in the groups given one, two or three consecutive applications oestrogen and progestagen (25 μg oestradiol benzoate followed 48 h later by a progestagen pessary left in situ for days). Of the 43 corpora lutea, 21 were represented by viable embryos in the 37 animals holding to service after one application compared with 34 out of 46 corpora lutea in 40 animals given three applications (P < 0·05). Furthermore, embryo crown-rump length, embryo weight and amniotic sac width was greater (P < 0·05), on day of pregnancy, in animals given one compared with three applications of oestrogen and progestagen. These results demonstrate that fertility is improved in ewe lambs mated on third oestrus or after progestagen and oestrogen therapy designed to simulate three oestrous cycles.


2012 ◽  
Vol 129 (3-5) ◽  
pp. 139-144 ◽  
Author(s):  
Yi Jin ◽  
Ling Duan ◽  
Mo Chen ◽  
Trevor M. Penning ◽  
Helenius J. Kloosterboer

1978 ◽  
Vol 76 (1) ◽  
pp. 21-31 ◽  
Author(s):  
M. T. VU HAI ◽  
E. MILGROM

SUMMARY The synthetic progestogen R5020 (17,21-dimethyl-19-norpregna-4,9-diene-3,20-dione) binds with high affinity (Ka = 8·8 × 108 1/mol at 0 °C) to the progesterone receptor from rat uterine cytosol. At nanomolar concentrations, equilibrium is attained in less than 90 min. R5020 has a very low affinity for other specific steroid-binding proteins (corticosteroid-binding globulin and oestrogen receptors) present in relatively high concentrations in the uterine cytosol. The affinity of the receptor for the natural hormone progesterone is remarkably low (Ka= 1 × 108−1·7 × 1081/mol at 0 °C) which explains the instability of progesterone–receptor complexes. Advantage may be taken of this property to remove endogenous progesterone easily by charcoal treatment at 0 °C, a treatment which does not modify the concentration of receptors. A method based on these characteristics is described for the assay of the total number (progesterone-bound and unbound) of receptor sites in uterine cytosol. This assay may be used in various physiological situations where endogenous progesterone is present at unknown concentrations.


1993 ◽  
Vol 129 (3) ◽  
pp. 225-228 ◽  
Author(s):  
Elizabeth Farish ◽  
Hilary A Rolton ◽  
Judith F Barnes ◽  
Colin D Fletcher ◽  
David J Walsh ◽  
...  

Epidemiological studies have shown that postmenopausal oestrogen therapy substantially reduces the risk of cardiovascular and cerebrovascular disease and this is partly mediated by oestrogen-associated changes in lipoproteins, particularly high-density lipoprotein. In this study, we investigated whether changes in lipoprotein(a) might help to account for the reduction in coronary heart disease and stroke associated with postmenopausal oestrogen therapy. The study group consisted of 18 women who had hysterectomy and bilateral oophorectomy at least 2 months prior to recruitment and had received no previous hormonal therapy. Serum samples were collected for measurement of lipoprotein(a) before and after 4 months of treatment with oestradiol valerate (2 mg/day). Lipoprotein(a) levels ranged from 35 to 720 mg/l (median 180 mg/l) before treatment and from 55 to 780 mg/l (median 1 30 mg/l) after oestradiol treatment and showed no consistent pattern of change. It would appear, therefore, that treatment with unopposed oestrogen in relatively low doses does not have a marked effect on lipoprotein(a), at least in the short term.


2006 ◽  
Vol 12 (1_suppl) ◽  
pp. 4-7 ◽  
Author(s):  
Malcolm Whitehead

A new form of continuous combined hormone replacement therapy has become available that contains estradiol and drospirenone as the progestogen component. Drospirenone is a synthetic progestogen, the only one in hormone replacement therapy in the UK that possesses clinically relevant anti-mineralocorticoid activity. The combination of estradiol and drospirenone has been shown to provide relief from estrogen-deficiency symptoms of the menopause. It also helps to prevent osteoporosis in postmenopausal women by increasing bone density. Further, it has been shown to provide protection against endometrial hyperplasia associated with unopposed estrogen therapy.


Sign in / Sign up

Export Citation Format

Share Document